← FDA Drug Approvals (Drugs@FDA)

OMCAZIO

NDA · New Drug Application · Sponsor: HANDA ONCOL · Approved 2026-09-03

Drug application

FDA Application #

NDA220613

Application type

New Drug Application

Brand name

OMCAZIO

Generic name

Cabozantinib Laurylsulfate

Active ingredients

CABOZANTINIB LAURYLSULFATE

Dosage form

CAPSULE

Route

ORAL

Marketing status

Prescription

Sponsor

HANDA ONCOL

First approval

2026-09-03

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown